These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25991652)

  • 21. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer's Disease.
    Saarelainen L; Taipale H; Koponen M; Tanskanen A; Tolppanen AM; Tiihonen J; Hartikainen S
    J Alzheimers Dis; 2016; 49(3):809-18. PubMed ID: 26484930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people.
    Reeve E; Ong M; Wu A; Jansen J; Petrovic M; Gnjidic D
    Eur J Clin Pharmacol; 2017 Aug; 73(8):927-935. PubMed ID: 28456823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of problematic behavioral symptoms associated with dementia: a cognitive developmental approach.
    Matteson MA; Linton AD; Cleary BL; Barnes SJ; Lichtenstein MJ
    Aging (Milano); 1997 Oct; 9(5):342-55. PubMed ID: 9458995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies.
    Rosenberg RP
    Ann Clin Psychiatry; 2006; 18(1):49-56. PubMed ID: 16517453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis.
    Zhao QF; Tan L; Wang HF; Jiang T; Tan MS; Tan L; Xu W; Li JQ; Wang J; Lai TJ; Yu JT
    J Affect Disord; 2016 Jan; 190():264-271. PubMed ID: 26540080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacologic treatment of Alzheimer's disease: a guide for the general psychiatrist.
    Flint AJ; van Reekum R
    Can J Psychiatry; 1998 Sep; 43(7):689-97. PubMed ID: 9773218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.
    Cummings J
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioural disturbances in psychiatric inpatients with dementia of the Alzheimer's type in Taiwan.
    Hwang JP; Yang CH; Tsai SJ; Liu KM
    Int J Geriatr Psychiatry; 1997 Sep; 12(9):902-6. PubMed ID: 9309467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease.
    Zubenko GS; Zubenko WN; McPherson S; Spoor E; Marin DB; Farlow MR; Smith GE; Geda YE; Cummings JL; Petersen RC; Sunderland T
    Am J Psychiatry; 2003 May; 160(5):857-66. PubMed ID: 12727688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sleep and agitation in nursing home residents with and without dementia.
    Brown DT; Westbury JL; Schüz B
    Int Psychogeriatr; 2015 Dec; 27(12):1945-55. PubMed ID: 26424155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review.
    Grimmer T; Kurz A
    Drugs Aging; 2006; 23(12):957-67. PubMed ID: 17154660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benzodiazepine use and risk of Alzheimer's disease: case-control study.
    Billioti de Gage S; Moride Y; Ducruet T; Kurth T; Verdoux H; Tournier M; Pariente A; Bégaud B
    BMJ; 2014 Sep; 349():g5205. PubMed ID: 25208536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care.
    Gallagher D; Herrmann N
    Neurodegener Dis Manag; 2015; 5(1):75-83. PubMed ID: 25711456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzodiazepines and risk of hip fractures in older people: a review of the evidence.
    Cumming RG; Le Couteur DG
    CNS Drugs; 2003; 17(11):825-37. PubMed ID: 12921493
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.